TrialsgrambetaRCTs are beautiful

KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis

This guideline cites 3 of the 58 landmark trials in our Nephrology register.

Issued by
KDIGO
Year
2024
Source
Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. Kidney Int. 2024;105(1S):S1–S69.doi 10.1016/j.kint.2023.09.002

The 2024 lupus-nephritis guideline replaces the corresponding chapter of the 2021 glomerular-diseases guideline. Its central shift is from monotherapy induction to routine triple therapy: glucocorticoids plus mycophenolate or low-dose cyclophosphamide, with belimumab or a calcineurin inhibitor (voclosporin) added upfront in class III/IV disease. Glucocorticoid exposure is cut sharply, treatment duration is defined by complete renal response rather than a fixed calendar, and repeat biopsy is given a clearer role. The register's trials behind each therapeutic pillar are grouped below.

Initial therapy: mycophenolate vs. cyclophosphamide1

  • 2009ALMS⁠Nephrology · Glomerular · Lupus nephritisIn 370 patients with active lupus nephritis, mycophenolate mofetil was non-inferior for induction response and superior for maintenance versus cyclophosphamide then azathioprine.Read →

Add-on B-cell targeting: belimumab1

  • 2020BLISS-LN⁠Nephrology · Glomerular · Lupus nephritisIn 448 patients with active lupus nephritis, adding belimumab to standard therapy increased renal response at week 104 compared with placebo.OR 1.55CI 1.04-2.32Read →

Calcineurin inhibition: voclosporin1

  • 2021AURORA 1⁠Nephrology · Glomerular · Lupus nephritisIn 357 patients with active lupus nephritis, adding voclosporin to MMF and low-dose steroids increased complete renal response at week 52 compared with placebo.OR 2.6595% CI 1.64-4.27Read →

Cited landmark trials not yet in the register5

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

  • 2002Euro-Lupus Nephritis Trial

    Low-dose intravenous cyclophosphamide matched the high-dose NIH regimen with less toxicity.

  • 2010MAINTAIN Nephritis

    Azathioprine vs. mycophenolate for maintenance after Euro-Lupus induction.

  • 2012LUNAR

    Rituximab added to mycophenolate missed its primary endpoint — rituximab stays a rescue option.

  • 2019AURA-LV

    Phase-2 voclosporin trial that set up AURORA 1.

  • 2014ACCESS

    Abatacept added to Euro-Lupus cyclophosphamide: no added benefit.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.